IO Biotech Inc
NASDAQ:IOBT

Watchlist Manager
IO Biotech Inc Logo
IO Biotech Inc
NASDAQ:IOBT
Watchlist
Price: 1.93 USD -1.03% Market Closed
Market Cap: 127.2m USD

EV/EBIT
Enterprise Value to EBIT

-0.9
Current
0.4
Median
5.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.9
=
Enterprise Value
90.1m USD
/
EBIT
-97.6m USD
Market Cap EV/EBIT
DK
IO Biotech Inc
NASDAQ:IOBT
127.2m USD -0.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -192 272.6
US
Abbvie Inc
NYSE:ABBV
337.1B USD 22.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 207.5
US
Amgen Inc
NASDAQ:AMGN
165.2B USD 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
145.3B USD 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD 27.3
US
Epizyme Inc
F:EPE
94.1B EUR -565.4
AU
CSL Ltd
ASX:CSL
130.4B AUD 23.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.3B USD 13.7
US
Seagen Inc
F:SGT
39.3B EUR -60.1
EBIT Growth EV/EBIT to Growth
DK
IO Biotech Inc
NASDAQ:IOBT
Average EV/EBIT: 21.1
Negative Multiple: -0.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 272.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.4 N/A N/A
AU
CSL Ltd
ASX:CSL
23.9
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.9
2-Years Forward
EV/EBIT
-0.9
3-Years Forward
EV/EBIT
-0.7